BPC-157Gut repair and soft-tissue recovery people actually ask for.
A body-protection peptide studied for gut healing, tendon and ligament repair, and inflammation — first access when compounding opens.
BPC-157 is the peptide members write in about most: stubborn gut lining issues, nagging tendons, and recovery that never quite finishes. An FDA advisory committee recommended it for compounding in July 2026. Join the waitlist for first access when pharmacy-sourced BPC-157 can be evaluated through AlphaMD.
By joining, you opt in to launch and marketing email about BPC-157 from AlphaMD. You can unsubscribe at any time.
- U.S. compounding pharmacies only
- Discreet shipping
- 100% confidential
Why BPC-157 Gets Attention
A healing signal borrowed from your own stomach lining.
BPC-157 is a 15-amino-acid chain derived from a protein found naturally in human gastric juice. Researchers isolated it while studying how the stomach lining repairs itself so quickly — then tested whether that same signal could support healing in gut, tendon, and other soft tissue.
In animal and cell studies, it appears to work upstream of repair: promoting new blood-vessel growth into damaged areas, calming inflammatory signaling, and supporting the cells that rebuild tendon, gut lining, and muscle. That breadth is why recovery-focused people keep asking for it.
Human trials exist for inflammatory bowel disease, and most other uses still rest on preclinical work. In July 2026 an FDA advisory committee recommended BPC-157 for the compounding bulk-substances list by a vote of 8 to 6 with one abstention — a step toward pharmacy compounding, not FDA approval of a finished drug.
Where BPC-157 Stands Today
- Recommended for compoundingAdvisory vote 8–6 (1 abstention), July 23, 2026
- FDA scientists advised against itAgency staff recommended no; the advisory committee voted yes 8–6
- Not an FDA-approved drugNo approved indication, no approved dosing label
- Banned in tested sportProhibited by WADA at all times
- Prescription-only at launchProvider evaluation and intake required — no direct purchase
Final compounding authorization still needs FDA rulemaking. The waitlist is how you get first access when a trusted pharmacy can lawfully produce and test it.
What You May Get From BPC-157
The upsides people care about — with a plain-language read on how strong the research is behind each one.
Gut lining repair
The most-studied use. Trialed in ulcerative colitis, where it appeared to reduce inflammation and support mucosal healing — the reason gut-focused members ask about it first.
Human trial dataTendon & ligament healing
Animal models of Achilles and rotator-cuff injury show faster repair and stronger reattachment of tendon to bone — the soft-tissue recovery story athletes chase.
Animal dataLower inflammatory signaling
Reduced pro-inflammatory markers across several injury models — a likely reason the repair effects show up across tissues.
Animal dataNew blood vessel growth
Promotes angiogenesis into injured tissue — more blood supply and faster delivery of what a wound needs to close.
Lab & animal dataSkin & wound closure
Faster closure of surgical and burn wounds in animal studies — part of why BPC-157 sits alongside KPV and TB-500 in recovery conversations.
Animal dataJoint comfort in daily life
The everyday ask: less nagging joint discomfort so training and life feel usable again. Common in member interest; still early as formal clinical proof.
Anecdotal onlyWho BPC-157 May Be A Fit For
A provider makes this call with you after reviewing your history and labs.
- Recovering from a soft-tissue injury — tendon, ligament, or muscle that hasn't fully come back.
- Managing an inflammatory gut condition — ulcerative colitis or IBD, alongside your gastroenterologist.
- Training hard in your 30s, 40s, or 50s and carrying nagging overuse pain that rest alone isn't fixing.
- Post-surgical and cleared to heal — with your surgeon's sign-off on adding anything new.
- Already an AlphaMD member on TRT and want recovery support tracked in the same care plan.
Who Should Skip It
Practical fit filters — a provider will decline when these apply.
- You have an active or recent cancer diagnosis. BPC-157 promotes blood-vessel growth; the effect on tumors is unstudied in humans.
- You compete in drug-tested sport. BPC-157 is prohibited by WADA at all times and will cost you eligibility.
- You're pregnant, nursing, or trying to conceive. No safety data exists in these groups.
- You're under 18, or you are unwilling to complete intake and follow-up labs.
- You need recovery basics covered first. Sleep, protein, load management, and hormone optimization still do the heavy lifting — peptides add to a plan, they do not replace one.
What To Know About Risks
Reported side effects are usually mild. Long-term human safety data is still thin — here is the practical picture.
Injection site reactions
Redness, itching, or a small lump at the site is the most commonly reported effect. Usually resolves in a day or two; rotating sites helps.
Nausea, headache, lightheadedness
Reported at higher doses. Often means the dose is too aggressive — tell your provider before you stop.
Limited long-term human safety data
There is no multi-year human safety study. That is why provider follow-up and labs matter when this launches.
Angiogenesis and cancer risk
Growing new blood vessels helps a wound heal. In theory the same mechanism could feed a tumor. Untested in humans — so an active or recent cancer history is a hard no.
Unknown drug interactions
No formal interaction studies exist. Bring your full medication and supplement list to your consult — including anything from elsewhere.
Gray-market product quality
Many reported "BPC-157 side effects" track to what was actually in the vial. Pharmacy-tested product is the point of waiting for a legitimate launch.
Pharmacy-Sourced Beats Gray-Market Guesswork
Most BPC-157 sold online today arrives from unregulated overseas labs labeled "for research use only." Independent testing of those vials keeps finding the same problems — which is exactly why AlphaMD is building the pharmacy path instead.
Gray-market vials
- Peptide content well under — or over — what the label claims
- Bacterial endotoxin from non-sterile production — a fever and sepsis risk you inject directly
- Residual synthesis solvents, heavy metals, and truncated peptide fragments
- Certificates of analysis that are copied, expired, or for an entirely different lot
- No prescriber, no recall path, and no one accountable if you're harmed
A U.S. compounding pharmacy
- State-licensed, FDA-inspected facility working from a real prescription
- Sterile compounding standards for anything injected, with documented process controls
- Third-party potency, sterility, and endotoxin testing tied to your specific lot
- A provider who sets your dose, reviews your labs, and owns follow-up
- Traceability — if a lot is bad, it can be found, pulled, and reported
When BPC-157 launches with AlphaMD, members get pharmacy-sourced product after a provider evaluation — not a research-chemical vial from a stranger.
Educational Resources
Deeper reading and video on the research, the July 2026 vote, and why sourcing decides most of the risk.
BPC-157: what the research actually shows
A licensed provider walks through the human trials, the animal data, the WADA status, and what to ask any clinic offering peptides today.
BPC-157 benefits, risks, and side effects, and what the FDA reviewed
The long-form deep dive: ulcerative colitis trials, animal repair data, WADA status, and what the July 2026 vote does and does not change.
Are your peptides even real? Why 1 in 5 tested vials came back mislabeled
Third-party assay results — potency, sterility, endotoxin, and what the labels claimed instead.
Frequently Asked Questions
Still deciding? Message the team — you don't need to be a member to ask.
Ask a QuestionFirst access when pharmacy-compounded BPC-157 can be offered through AlphaMD — plus the path that matters: a provider evaluation, intake, and product from a U.S. compounding pharmacy with lot-level testing. No date invented; you hear as soon as launch is real.
In July 2026 an FDA advisory committee recommended BPC-157 for the 503A bulk-substances list — a recommendation, not final rulemaking. Notice-and-comment could run into 2027 or beyond. Until that finishes, pharmacies cannot compound it under the usual categories. Once a pharmacy AlphaMD trusts can lawfully produce and test it, the waitlist gets the email that week.
Not yet. Nothing on this page is for sale. If a clinic is offering BPC-157 today, ask which licensed U.S. pharmacy compounded it and for lot-specific sterility and potency testing. Most cannot show either.
In research it is most often a small subcutaneous injection, with oral and topical forms studied for gut and skin use. Route and dose are set with a provider at consult — there is no approved label to copy from.
No known interaction, and many members asking about BPC-157 are already on testosterone. Raising it in the same care plan keeps dose changes and bloodwork in one place.
Possession is not a criminal matter for individuals, but it is not an approved drug, and selling it for human use is not lawful — hence the gray-market "research use only" label. The legitimate path is a prescription after provider evaluation, filled by a licensed compounding pharmacy.
Skip it. BPC-157 is on the WADA prohibited list at all times. It will not be prescribed to a tested athlete through AlphaMD.
Pricing is not set until a supplier is locked. When it is, it will be published the same way TRT pricing is: one clear number, per month.
Explore Other Peptides
Five more on the same July 2026 compounding slate — join each waitlist for first access when they launch.
Get First Access to BPC-157
Join the waitlist for pharmacy-sourced BPC-157 through AlphaMD — provider evaluation, tested product, discreet shipping. Already a member? Bring peptides up at your next visit or book a consult to get intake done early.
By joining, you opt in to launch and marketing email about BPC-157 from AlphaMD. You can unsubscribe at any time.
No insurance needed · Cancel anytime · 100% confidential
Legal Disclaimer
BPC-157 is not an FDA-approved drug and is not currently available for sale or prescription through AlphaMD. Nothing on this page is an offer to sell, and nothing here is medical advice. Statements about potential benefits describe published preclinical and early clinical research and are not claims about outcomes for any individual. Peptide therapy, if and when offered, will require a consultation with a licensed medical professional, a completed medical intake, and appropriate laboratory testing; it is not appropriate for everyone. BPC-157 is prohibited by the World Anti-Doping Agency at all times.
Medical services are provided by independent, licensed providers through AlphaMD's affiliated professional practices. AlphaMD provides administrative and technology services and does not practice medicine.